IPIC Message Board - Msg: 3904391

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

0.0%

Aug 15 3:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pancho Villa who wrote (1124)	3/31/1998 4:13:00 PM
From: WeirdPro Randy	Read Replies (2) of 1359

<<Three questions: <<Does the study decrease potential liability for the patients that may show damage from the version that was marketed?>> It will make it much more difficult to prove causality of damage...legally makes it a more difficult issue to bring to trial. <<Given the troublesome history of the initial approval, what are the chances the FDA ever approesl for the sustained release version.>> This study released today has nothing to do with looking to market the sustained release version of Redux. Anyway, neither AHP or IPIC would be looking try. <<I wonder what other experts will have to say about these results.>> The experts have largely been laughing at the Mayo clinic "study", this is the first true double-blinded study on this issue. I would think they are going to put great faith in this study compared to anything else available currently. <<And, who paid for this study? Seems to me that if AHP/IPIC paid there is a built in bias to soften possible valve anormality reading from the electro regardless of the group.>> AHP paid for it......and from beginning to end, nobody including the patients, knew what they had been given during this study. Hey!...that's 4 questions.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next